Tempei Otsubo
   Department   School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine
   Position   Professor
Article types Original article
Language English
Peer review Peer reviewed
Title Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.
Journal Formal name：Frontiers in psychiatry
Abbreviation：Front Psychiatry
ISSN code：16640640/16640640
Domestic / ForeginForegin
Volume, Issue, Page 14,pp.1083568
Author and coauthor Aoki Yumi, Takaesu Yoshikazu, Inada Ken, Yamada Hiroki, Murao Tomohiko, Kikuchi Toshiaki, Takeshima Masahiro, Tani Masayuki, Mishima Kazuo, Otsubo Tempei
Publication date 2023
Summary AIM:We aimed to develop a decision aid (DA) for individuals with anxiety disorders who consider tapering benzodiazepine (BZD) anxiolytics, and if tapering, tapering BZD anxiolytics with or without cognitive behavioral therapy (CBT) for anxiety. We also assessed its acceptability among stakeholders.METHODS:First, we conducted a literature review regarding anxiety disorders to determine treatment options. We cited the results of the systematic review and meta-analysis, which we conducted previously, to describe the related outcomes of two options: tapering BZD anxiolytics with CBT and tapering BZD anxiolytics without CBT. Second, we developed a DA prototype in accordance with the International Patient Decision Aid Standards. We carried out a mixed methods survey to assess the acceptability among stakeholders including those with anxiety disorders and healthcare providers.RESULTS:Our DA provided information such as explanation of anxiety disorders, options of tapering or not tapering BZD anxiolytics (if tapering, the options of tapering BZD anxiolytics with or without CBT) for anxiety disorder, benefits and risks of each option, and a worksheet for value clarification. For patients (n = 21), the DA appeared to be acceptable language (86%), adequate information (81%), and well-balanced presentation (86%). The developed DA was also acceptable for healthcare providers (n = 10).CONCLUSION:We successfully created a DA for individuals with anxiety disorders who consider tapering BZD anxiolytics, which was acceptable for both patients and healthcare providers. Our DA was designed to assist patients and healthcare providers to involve decision-making about whether to taper BZD anxiolytics or not.
DOI 10.3389/fpsyt.2023.1083568
PMID 37252154